Blue Water Acquisition Corp. III (BLUW) Competitors

$10.27 +0.02 (+0.16%)

As of 05/15/2026 04:00 PM Eastern

BLUW vs. PLX, IZTC, JATT, ALVR, and ZIVO

Should you buy Blue Water Acquisition Corp. III stock or one of its competitors? MarketBeat compares Blue Water Acquisition Corp. III with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Blue Water Acquisition Corp. III include Protalix BioTherapeutics (PLX), Invizyne Technologies (IZTC), JATT Acquisition (JATT), AlloVir (ALVR), and ZIVO Bioscience (ZIVO). These companies are all part of the "medical" sector.

How does Blue Water Acquisition Corp. III compare to Protalix BioTherapeutics?

Blue Water Acquisition Corp. III (NASDAQ:BLUW) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Blue Water Acquisition Corp. III has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Blue Water Acquisition Corp. III's return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blue Water Acquisition Corp. III	N/A	N/A	N/A
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Protalix BioTherapeutics has higher revenue and earnings than Blue Water Acquisition Corp. III.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A
Protalix BioTherapeutics	$52.74M	3.02	$8.31M	$0.18	11.00

In the previous week, Protalix BioTherapeutics had 5 more articles in the media than Blue Water Acquisition Corp. III. MarketBeat recorded 8 mentions for Protalix BioTherapeutics and 3 mentions for Blue Water Acquisition Corp. III. Blue Water Acquisition Corp. III's average media sentiment score of 1.32 beat Protalix BioTherapeutics' score of 0.15 indicating that Blue Water Acquisition Corp. III is being referred to more favorably in the media.

Company	Overall Sentiment
Blue Water Acquisition Corp. III	Positive
Protalix BioTherapeutics	Neutral

Protalix BioTherapeutics has a consensus price target of $12.00, suggesting a potential upside of 506.06%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Blue Water Acquisition Corp. III.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Protalix BioTherapeutics beats Blue Water Acquisition Corp. III on 7 of the 11 factors compared between the two stocks.

How does Blue Water Acquisition Corp. III compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and Blue Water Acquisition Corp. III (NASDAQ:BLUW) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Blue Water Acquisition Corp. III	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A

In the previous week, Blue Water Acquisition Corp. III had 3 more articles in the media than Invizyne Technologies. MarketBeat recorded 3 mentions for Blue Water Acquisition Corp. III and 0 mentions for Invizyne Technologies. Blue Water Acquisition Corp. III's average media sentiment score of 1.32 beat Invizyne Technologies' score of 0.00 indicating that Blue Water Acquisition Corp. III is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
Blue Water Acquisition Corp. III	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Blue Water Acquisition Corp. III beats Invizyne Technologies on 3 of the 3 factors compared between the two stocks.

How does Blue Water Acquisition Corp. III compare to JATT Acquisition?

JATT Acquisition (NYSE:JATT) and Blue Water Acquisition Corp. III (NASDAQ:BLUW) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A

In the previous week, Blue Water Acquisition Corp. III had 3 more articles in the media than JATT Acquisition. MarketBeat recorded 3 mentions for Blue Water Acquisition Corp. III and 0 mentions for JATT Acquisition. Blue Water Acquisition Corp. III's average media sentiment score of 1.32 beat JATT Acquisition's score of 0.00 indicating that Blue Water Acquisition Corp. III is being referred to more favorably in the news media.

Company	Overall Sentiment
JATT Acquisition	Neutral
Blue Water Acquisition Corp. III	Positive

48.0% of JATT Acquisition shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Blue Water Acquisition Corp. III's return on equity of 0.00% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Blue Water Acquisition Corp. III	N/A	N/A	N/A

Summary

Blue Water Acquisition Corp. III beats JATT Acquisition on 4 of the 7 factors compared between the two stocks.

How does Blue Water Acquisition Corp. III compare to AlloVir?

Blue Water Acquisition Corp. III (NASDAQ:BLUW) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

In the previous week, Blue Water Acquisition Corp. III had 3 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Blue Water Acquisition Corp. III and 0 mentions for AlloVir. Blue Water Acquisition Corp. III's average media sentiment score of 1.32 beat AlloVir's score of 0.00 indicating that Blue Water Acquisition Corp. III is being referred to more favorably in the media.

Company	Overall Sentiment
Blue Water Acquisition Corp. III	Positive
AlloVir	Neutral

66.1% of AlloVir shares are owned by institutional investors. 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Blue Water Acquisition Corp. III's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blue Water Acquisition Corp. III	N/A	N/A	N/A
AlloVir	N/A	-71.03%	-61.27%

Summary

Blue Water Acquisition Corp. III beats AlloVir on 5 of the 7 factors compared between the two stocks.

How does Blue Water Acquisition Corp. III compare to ZIVO Bioscience?

Blue Water Acquisition Corp. III (NASDAQ:BLUW) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Blue Water Acquisition Corp. III has higher earnings, but lower revenue than ZIVO Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A
ZIVO Bioscience	$15.85K	966.62	-$7.78M	-$2.59	N/A

In the previous week, Blue Water Acquisition Corp. III had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 3 mentions for Blue Water Acquisition Corp. III and 1 mentions for ZIVO Bioscience. Blue Water Acquisition Corp. III's average media sentiment score of 1.32 beat ZIVO Bioscience's score of 0.00 indicating that Blue Water Acquisition Corp. III is being referred to more favorably in the media.

Company	Overall Sentiment
Blue Water Acquisition Corp. III	Positive
ZIVO Bioscience	Neutral

12.8% of ZIVO Bioscience shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Blue Water Acquisition Corp. III	N/A	N/A	N/A
ZIVO Bioscience	N/A	N/A	-2,240.92%

Summary

Blue Water Acquisition Corp. III beats ZIVO Bioscience on 4 of the 7 factors compared between the two stocks.

Get Blue Water Acquisition Corp. III News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLUW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLUW vs. The Competition

Export

Metric	Blue Water Acquisition Corp. III	Biological Products, Except Diagnostic Industry	Medical Sector	NASDAQ Exchange
Market Cap	$288.23M	$327.98M	$6.33B	$12.47B
Dividend Yield	N/A	N/A	2.80%	5.28%
P/E Ratio	N/A	N/A	20.07	25.23
Price / Sales	N/A	171.74	551.32	83.22
Price / Cash	N/A	22.44	43.04	56.04
Price / Book	N/A	4.73	9.83	6.91
Net Income	N/A	-$132.96M	$3.56B	$334.11M
7 Day Performance	0.10%	3.24%	0.25%	0.01%
1 Month Performance	0.16%	11.44%	-1.30%	1.17%
1 Year Performance	6.65%	56.70%	33.61%	30.68%

Blue Water Acquisition Corp. III Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLUW Blue Water Acquisition Corp. III	N/A	$10.27 +0.2%	N/A	+6.6%	$288.23M	N/A	N/A	2	Positive News Earnings Report Short Interest Decrease
PLX Protalix BioTherapeutics	2.8636 of 5 stars	$1.94 -2.0%	$12.00 +518.6%	+18.6%	$159.53M	$52.74M	N/A	200	News Coverage
IZTC Invizyne Technologies	N/A	$9.62 -3.8%	N/A	-32.1%	$103.16M	N/A	N/A	29
JATT JATT Acquisition	N/A	$10.76 +2.4%	N/A	+799.1%	$83.89M	N/A	N/A	3
ALVR AlloVir	N/A	$5.08 -1.4%	N/A	+54.4%	$25.62M	N/A	N/A	110	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLUW) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blue Water Acquisition Corp. III (BLUW) Competitors

BLUW vs. PLX, IZTC, JATT, ALVR, and ZIVO

How does Blue Water Acquisition Corp. III compare to Protalix BioTherapeutics?

Summary

How does Blue Water Acquisition Corp. III compare to Invizyne Technologies?

Summary

How does Blue Water Acquisition Corp. III compare to JATT Acquisition?

Summary

How does Blue Water Acquisition Corp. III compare to AlloVir?

Summary

How does Blue Water Acquisition Corp. III compare to ZIVO Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLUW vs. The Competition

Blue Water Acquisition Corp. III Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Blue Water Acquisition Corp. III (BLUW) Competitors

BLUW vs. PLX, IZTC, JATT, ALVR, and ZIVO

How does Blue Water Acquisition Corp. III compare to Protalix BioTherapeutics?

Do institutionals & insiders have more ownership in BLUW or PLX?

Is BLUW or PLX more profitable?

Which has better earnings and valuation, BLUW or PLX?

Does the media prefer BLUW or PLX?

Do analysts rate BLUW or PLX?

Summary

How does Blue Water Acquisition Corp. III compare to Invizyne Technologies?

Is IZTC or BLUW more profitable?

Which has higher valuation & earnings, IZTC or BLUW?

Does the media prefer IZTC or BLUW?

Do analysts prefer IZTC or BLUW?

Summary

How does Blue Water Acquisition Corp. III compare to JATT Acquisition?

Which has stronger valuation and earnings, JATT or BLUW?

Does the media prefer JATT or BLUW?

Do insiders & institutionals hold more shares of JATT or BLUW?

Do analysts prefer JATT or BLUW?

Is JATT or BLUW more profitable?

Summary

How does Blue Water Acquisition Corp. III compare to AlloVir?

Which has better valuation and earnings, BLUW or ALVR?

Does the media refer more to BLUW or ALVR?

Do institutionals & insiders hold more shares of BLUW or ALVR?

Do analysts prefer BLUW or ALVR?

Is BLUW or ALVR more profitable?

Summary

How does Blue Water Acquisition Corp. III compare to ZIVO Bioscience?

Which has better valuation and earnings, BLUW or ZIVO?

Does the media refer more to BLUW or ZIVO?

Do institutionals & insiders hold more shares of BLUW or ZIVO?

Do analysts prefer BLUW or ZIVO?

Is BLUW or ZIVO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLUW vs. The Competition

Blue Water Acquisition Corp. III Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools